Zai Lab Ltd (HK:9688)
:9688
Want to see HK:9688 full AI Analyst Report?
9688 Stock Chart & Stats
HK$18.27
-HK$0.02(-0.10%)
At close: 4:00 PM EST
HK$18.27
-HK$0.02(-0.10%)
Day’s Range― - ―
52-Week RangeHK$12.31 - HK$35.50
Previous CloseN/A
Volume1.30M
Average Volume (3M)10.12M
Market Cap
HK$19.93B
Enterprise ValueHK$1.99B
Total Cash (Recent Filing)HK$789.47M
Total Debt (Recent Filing)HK$237.61M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
May 07, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding1,134,128,000
10 Day Avg. Volume10,854,931
30 Day Avg. Volume10,116,373
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.68
Price to Sales (P/S)4.17
P/FCF Ratio-12.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.62Price Target Upside40.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.47
Revenue Forecast (FY)HK$3.85B
Bulls Say, Bears Say
Bulls Say
Revenue ScalingSustained multi‑year revenue growth to $460.8M in 2025 indicates durable commercial traction and market adoption in Greater China. A much larger revenue base improves operating leverage potential, supports reinvestment in R&D and commercialization, and underpins future scale.
Healthy Gross MarginsGross margins around 58% reflect strong product‑level economics and pricing power versus peers. High margins provide durable buffer to absorb SG&A and R&D spending, enabling sustained reinvestment to expand indications and sales infrastructure while improving path toward profitability.
Commercial + Partnership ModelA mixed revenue model—direct product sales plus collaboration and licensing income—diversifies cash flow sources. Durable partnerships can deliver upfront/milestone payments and local commercialization synergies, lowering single‑asset risk and enhancing scalability across therapeutic areas in Greater China.
Bears Say
Significant Cash BurnContinued large negative operating and free cash flow constrains financial flexibility and increases reliance on external funding. Persistent cash burn can force dilutive equity raises or debt, limiting ability to self‑fund late‑stage trials and commercialization investments over the medium term.
Persistent LossesDeep negative operating and net margins show the company has not yet converted revenue scale into profitability. Sustained losses weaken returns on capital, pressure retained earnings, and signal that operating leverage and cost structure still need structural improvement to generate durable shareholder value.
Rising Leverage & Negative ROEHigher leverage alongside a negative ROE reflects rising financial risk while shareholder capital is being eroded. Debt increases fixed obligations and can restrict strategic flexibility; negative returns reduce capacity to absorb further financing costs without diluting or stressing the balance sheet.
Zai Lab Ltd News
9688 FAQ
What was Zai Lab Ltd’s price range in the past 12 months?
Zai Lab Ltd lowest stock price was HK$12.31 and its highest was HK$35.50 in the past 12 months.
What is Zai Lab Ltd’s market cap?
Zai Lab Ltd’s market cap is HK$19.93B.
When is Zai Lab Ltd’s upcoming earnings report date?
Zai Lab Ltd’s upcoming earnings report date is May 07, 2026 which is in 9 days.
How were Zai Lab Ltd’s earnings last quarter?
Zai Lab Ltd released its earnings results on Feb 26, 2026. The company reported -HK$0.36 earnings per share for the quarter, missing the consensus estimate of -HK$0.273 by -HK$0.087.
Is Zai Lab Ltd overvalued?
According to Wall Street analysts Zai Lab Ltd’s price is currently Undervalued.
Does Zai Lab Ltd pay dividends?
Zai Lab Ltd does not currently pay dividends.
What is Zai Lab Ltd’s EPS estimate?
Zai Lab Ltd’s EPS estimate is -0.39.
How many shares outstanding does Zai Lab Ltd have?
Zai Lab Ltd has 1,134,128,000 shares outstanding.
What happened to Zai Lab Ltd’s price movement after its last earnings report?
Zai Lab Ltd reported an EPS of -HK$0.36 in its last earnings report, missing expectations of -HK$0.273. Following the earnings report the stock price went down -3.079%.
Which hedge fund is a major shareholder of Zai Lab Ltd?
Currently, no hedge funds are holding shares in HK:9688
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zai Lab Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$25.62 (40.25% Upside)
HK$25.62 (40.25% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-22.81%
Trailing 12-Months
Asset Growth
-12.83%
Trailing 12-Months
Company Description
Zai Lab Ltd
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
9688 Stock 12 Month Forecast
Average Price Target
HK$25.62
▲(40.25% Upside)
Technical Analysis
Alphamab Oncology
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Lepu Biopharma Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---